Skip to main content
. 2017 Jun 5;114(25):E4924–E4933. doi: 10.1073/pnas.1615730114

Fig. 6.

Fig. 6.

Inhibition of tumor growth and impairment of tumor-initiating stem-like cells in vivo. (A and B) STAT3, pSTAT3, and Ki67 in DU145 tumor xenografts after treatment with OPB-51602 (40 mg/kg, daily by mouth) for 3 and 5 d and off treatment for 2 d (5+2). Representative images (A) and IHC quantification (B). (C) Aggresome formation in DU145 tumor xenografts from control and OPB-51602–treated mice (40 mg/kg, daily by mouth) detected by ProteoStat staining (Upper) or p62 immunostaining (Lower). Arrows, large aggregates in drug-treated xenografts. (D) Growth of tumor xenografts of DU145 cells in mice treated with 20 mg⋅kg⋅d–1 of OPB-51602 (n = 5 per group). (E and F), pTyr705 STAT3, pSer727 STAT3, and Ki67 IHC in tumor xenografts of DU145 cells in mice treated with vehicle or 20 mg⋅kg⋅d–1 OPB-51602 for 2 wk. Quantification of pTyr705, pSer727 STAT3 and Ki67 immuno-staining (E) and representative images (F). *P < 0.01.